Medivation Reaches New 52-Week High (MDVN)

NEW YORK ( TheStreet) -- Medivation (Nasdaq: MDVN) hit a new 52-week high Wednesday as it is currently trading at $97.64, above its previous 52-week high of $97.09 with 18,572 shares traded as of 9:40 a.m. ET. Average volume has been 741,800 shares over the past 30 days.

Medivation has a market cap of $3.46 billion and is part of the health care sector and drugs industry. Shares are up 108.3% year to date as of the close of trading on Tuesday.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins, weak operating cash flow and generally poor debt management. You can view the full Medivation Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors